MA25284A1 - Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose. - Google Patents

Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.

Info

Publication number
MA25284A1
MA25284A1 MA25719A MA25719A MA25284A1 MA 25284 A1 MA25284 A1 MA 25284A1 MA 25719 A MA25719 A MA 25719A MA 25719 A MA25719 A MA 25719A MA 25284 A1 MA25284 A1 MA 25284A1
Authority
MA
Morocco
Prior art keywords
carnitine
glucose
improves
antioxidant composition
including acetylene
Prior art date
Application number
MA25719A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of MA25284A1 publication Critical patent/MA25284A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNE COMPOSITION EST DIVULGUÉE ET QUI COMPREND COMME INGRÉDIENTS ACTIFS CARACTÉRISTIQUES L'ACÉTYL L-CARNITINE ET L'ACIDE DÉLTA-LIPOiQUE, POUR LA PRÉVENTION ET/OU POUR LE TRAITEMENT THÉRAPEUTIQUE DES DIFFÉRENTES ALTÉRATIONS ET DES ÉTATS PATHOLOGIQUES INDUITS PAR LA PRÉSENCE DE RADICAUX à L'ÉTAT LIBRE, ET QUI PEUT eTRE SOUS FORME D'UN SUPPLÉMENT DIÉTÉTIQUE, UN SUPPORT DIÉTÉTIQUE OU UN MÉDICAMENT EFFECTIF.
MA25719A 1998-09-01 1999-08-06 Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose. MA25284A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil

Publications (1)

Publication Number Publication Date
MA25284A1 true MA25284A1 (fr) 2001-12-31

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25719A MA25284A1 (fr) 1998-09-01 1999-08-06 Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.

Country Status (28)

Country Link
US (1) US6365622B1 (fr)
EP (1) EP1112005B2 (fr)
JP (1) JP4361215B2 (fr)
KR (1) KR20010079699A (fr)
CN (1) CN1315835A (fr)
AR (1) AR022076A1 (fr)
AT (1) ATE228312T1 (fr)
AU (1) AU773424B2 (fr)
BR (1) BR9913288A (fr)
CA (1) CA2341973C (fr)
CZ (1) CZ2001541A3 (fr)
DE (1) DE69904208T3 (fr)
DK (1) DK1112005T4 (fr)
EE (1) EE200100113A (fr)
ES (1) ES2188214T5 (fr)
HK (1) HK1039730A1 (fr)
HU (1) HU229165B1 (fr)
IL (1) IL141435A0 (fr)
IS (1) IS5850A (fr)
IT (1) IT1302307B1 (fr)
MA (1) MA25284A1 (fr)
NO (1) NO20010954L (fr)
PL (1) PL212737B1 (fr)
PT (1) PT1112005E (fr)
SK (1) SK2632001A3 (fr)
TN (1) TNSN99163A1 (fr)
TR (1) TR200100610T2 (fr)
WO (1) WO2000011968A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
AU7828200A (en) 1999-09-23 2001-04-24 Juvenon Corporation Nutritional supplement for increased energy and stamina
EP1248609A4 (fr) * 1999-11-03 2007-08-01 Juvenon Inc Traitement de la perte de memoire benigne
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
CA2427470A1 (fr) * 2000-10-31 2002-06-06 Colgate-Palmolive Company Composition et methode
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
JP2005518381A (ja) * 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
AU2003219880A1 (en) * 2002-02-22 2003-09-09 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
US20040132821A1 (en) * 2002-10-11 2004-07-08 Roberto Crea Therapeutic combination of carnitine and antioxidant polyphenols
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US7999003B2 (en) 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
WO2005067972A1 (fr) 2003-12-31 2005-07-28 Integrative Health Consulting, Inc. Compositions nutritives et methodes permettant d'ameliorer l'efficacite du systeme immunitaire
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CA2588709C (fr) * 2004-11-24 2015-07-14 Hill's Pet Nutrition, Inc. Utilisation de l'acide lipoique pour ameliorer la clairance hepatique des substances xenobiotiques
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
CN101106984B (zh) * 2004-11-24 2012-10-24 希尔氏宠物营养品公司 包含硫辛酸的组合物及其用途
DK1830883T3 (da) 2004-12-29 2013-11-25 Hills Pet Nutrition Inc Fremgangsmåde til at hæmme en nedgang i indlæring og/eller hukommelse hos dyr
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN102907561A (zh) * 2004-12-30 2013-02-06 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
BRPI0613000A2 (pt) 2005-07-14 2012-12-04 Hills Pet Nutrition Inc método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição
WO2007095760A1 (fr) * 2006-02-23 2007-08-30 Nou Life Sciences, Inc. Dérivé clivable de carnitine
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
WO2009020317A2 (fr) * 2007-08-06 2009-02-12 Biogenics, Inc. Particules antioxydantes stabilisées, composition les contenant et leur procédé de préparation
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-ｌ-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP2012508267A (ja) * 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
EP2389931A1 (fr) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Compositions pharmaceutiques aqueuses comprenant de l'acide lipoïque en tant qu'antioxydant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CN104114152A (zh) 2011-12-07 2014-10-22 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US11337960B2 (en) 2014-10-24 2022-05-24 Pre-D Partners Llc Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
UA121399C2 (uk) 2014-11-25 2020-05-25 Аллерган, Інк. Стабілізовані композиції для офтальмологічного застосування, які містять омега-3-кислоти
US10413526B2 (en) 2015-03-31 2019-09-17 Kolinpharma S.P.A. Composition for the treatment of neuropathies and/or neuropathic pain
JP6918782B2 (ja) * 2015-08-24 2021-08-11 ヴィトロライフ スウェーデン アクチボラゲット 培養培地
WO2020053754A1 (fr) * 2018-09-10 2020-03-19 Uriach Italia S.R.L. Composition comprenant de l'acide lipoïque et de la vitamine d pour la prévention et le traitement de maladies neurodégénératives et de neuropathies périphériques
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
ES2889587T3 (es) * 2019-04-18 2022-01-12 Simo Rasi Composición para su uso en la prevención o reducción del estrés oxidativo y de enfermedades neurodegenerativas
WO2022215085A1 (fr) * 2021-04-06 2022-10-13 Celagenex Research (India) Pvt. Ltd. Composition synergique pour potentialiser l'atp stabilisée
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1997002041A1 (fr) * 1995-07-03 1997-01-23 Crandall Wilson T Traitement transcutane et oral de l'alopecie androgene
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
AU6141498A (en) 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Also Published As

Publication number Publication date
ES2188214T5 (es) 2010-06-08
DE69904208T3 (de) 2010-09-30
ATE228312T1 (de) 2002-12-15
SK2632001A3 (en) 2001-08-06
EP1112005A1 (fr) 2001-07-04
IT1302307B1 (it) 2000-09-05
BR9913288A (pt) 2001-05-22
PT1112005E (pt) 2003-03-31
JP4361215B2 (ja) 2009-11-11
CN1315835A (zh) 2001-10-03
PL346318A1 (en) 2002-01-28
TNSN99163A1 (fr) 2005-11-10
CA2341973A1 (fr) 2000-03-09
AU773424B2 (en) 2004-05-27
WO2000011968A8 (fr) 2000-05-11
DK1112005T4 (da) 2010-06-14
KR20010079699A (ko) 2001-08-22
HUP0102909A2 (hu) 2002-03-28
DE69904208D1 (de) 2003-01-09
IL141435A0 (en) 2002-03-10
ITRM980566A1 (it) 2000-03-01
EP1112005B1 (fr) 2002-11-27
AU5387199A (en) 2000-03-21
AR022076A1 (es) 2002-09-04
IS5850A (is) 2001-02-16
HUP0102909A3 (en) 2002-12-28
DE69904208T2 (de) 2003-08-28
NO20010954D0 (no) 2001-02-26
ITRM980566A0 (it) 1998-09-01
NO20010954L (no) 2001-04-25
HK1039730A1 (zh) 2002-05-10
EE200100113A (et) 2002-06-17
JP2002523435A (ja) 2002-07-30
HU229165B1 (en) 2013-09-30
CA2341973C (fr) 2009-05-12
TR200100610T2 (tr) 2001-07-23
DK1112005T3 (da) 2002-12-30
WO2000011968A1 (fr) 2000-03-09
US6365622B1 (en) 2002-04-02
PL212737B1 (pl) 2012-11-30
EP1112005B2 (fr) 2010-03-24
CZ2001541A3 (cs) 2001-09-12
ES2188214T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN96107A1 (fr) Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant
CA2191789A1 (fr) Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
BE901737A (fr) Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue.
MA26671A1 (fr) COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES
BE901994A (fr) Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
CA2331395A1 (fr) Nouveaux analogues d'acides gras destines au traitement du diabete
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99135A1 (fr) Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
CA2259621A1 (fr) Derives d'isocoumarine et utilisation de ces derniers dans des medicaments
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
DE69526353D1 (de) Immunologische aktivität der rhamnolipide
TNSN00077A1 (fr) Une composition comportant un carnitine et du glutathione, utilisable pour augmenter l'absorption du glutathione et synergiser ces effets
CA2191790A1 (fr) Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00083A1 (fr) Une composition contenant un carnitine et un phosphate d'inositol utilisee comme supplement dietetique ou medicament
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
BE902796A (fr) Ester d'acetyl carnitine, sa preparation et son utilisation.